Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR5A | P47898 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616744 | 1.00 | HTR7 (0.64) | HTR7LMNASIGMAR1HTR6HTR1A | |
| SCHEMBL1138323 | 0.87 | HTR7 (0.57) | HTR7LMNASIGMAR1CXCR4DRD2 | |
| SCHEMBL32667521 | 0.87 | HTR7 (0.57) | HTR7LMNASIGMAR1CXCR4DRD2 | |
| SCHEMBL7101510 | 0.87 | LMNA (0.53) | HTR7LMNASIGMAR1CXCR4DRD2 | |
| SCHEMBL7097403 | 0.87 | HTR7 (0.62) | HTR7LMNASIGMAR1HTR6CXCR4 | |
| SCHEMBL7098277 | 0.87 | LMNA (0.53) | HTR7LMNASIGMAR1HTR6HTR1A | |
| SCHEMBL376781 | 0.87 | HTR7 (0.56) | HTR7LMNASIGMAR1CXCR4MLNR | |
| SCHEMBL28230641 | 0.87 | HTR7 (0.80) | HTR7SIGMAR1DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL5689236 | 0.86 | HTR7 (0.55) | HTR7LMNASIGMAR1CXCR4MLNR | |
| Hydrochloric Acid SCHEMBL30688262 | 0.86 | HTR7 (0.55) | HTR7LMNASIGMAR1CXCR4MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112585139-A | Nalidinone compounds as T cell activators | 百时美施贵宝公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-12-20 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2373629-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
| CN-1149214-C | Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient | ������������ʽ���� | 2004-05-12 | — | — | CN | disclosed |
| US-6492364-B1 | Triazolo and derivatives as chemokine inhibitors | TORAY INDUSTRIES, INC. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1293674-A | Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient | TORAY INDUSTRIES (JP) | 2001-05-02 | — | — | CN | disclosed |
| EP-1067130-A1 | TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BCL2, BAX, BCL2A1 | HTR7 2753/4885LMNA 2691/4885SIGMAR1 2448/4885 |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | HTR7 4449/4885LMNA 2011/4885SIGMAR1 3016/4885 |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | CASP3, CASP5, CASP6 | HTR7 3980/4885LMNA 294/4885SIGMAR1 4613/4885 |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | HTR7 4449/4885LMNA 2011/4885SIGMAR1 3016/4885 |
| US-10022371-B2 | Procaspase-activating compounds and methods | CASP3, CASP5, CASP6 | HTR7 3980/4885LMNA 294/4885SIGMAR1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.